Oculis Holding AG (OCS) Stock AnalysisOCSOculis Holding AG

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide. It operates in the Healthcare sector.

Oculis Holding AG is currently not a strong buy due to its low RSI of 24.749, indicating oversold conditions, and a significant YTD change of -38.95%. While the recent positive FDA feedback on Privosegtor could provide future upside, the company has reported consistent losses, with a net income of -28,852,000 CHF in Q1 2026 and a forward P/E of 0, suggesting uncertainty in profitability. The primary risk is the ongoing negative sentiment reflected in the stock's decline and the downgrades from analysts, with the lowest target at $23, which is significantly below the current price of $12.21.